[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"glycemic-control\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:glycemic-control":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,45,75,105,141,168,194,218],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100596312","impact-of-pharmate-trial-on-glycemic-control-diabetes-knowledge-medication-adherence-and-quality-of-life-in-type-2-diabetes-patients-a-mixed-method-study-protocol-100596312",false,"NCT07043816","Impact of PharmaTE Trial on Glycemic Control, Diabetes Knowledge, Medication Adherence and Quality of Life in Type 2 Diabetes Patients: A Mixed-Method Study Protocol","PharmaTE","Inclusion Criteria\n\n* Patients diagnosed with uncontrolled type 2 diabetes (defined as glycated haemoglobin \\[HbA1c\\] \\>7%) within the previous 12 months\n* Adults (18 to 65 years) of either gender\n* Prescribed at least one antidiabetic medication\n* Have access to either a telephone or a mobile phone\n* Treated in an outpatient facility in IBOH, RAK\n* Arabic-speaking patients\n* Patients who understand study information and are given written informed consent.\n\nExclusion Criteria:\n\n* Under 18 years old\n* Pregnant ladies\n* Patients admitted to the emergency department\n* Patients with severe hepatic or renal dysfunction\n* Diagnosed with type 1 DM or diagnosed with gestational diabetes\n* Having vision or hearing impairments and psychological problems\n* Immunocompromised patients, e.g., organ transplants, AIDS, cancer patients, and patients on immunosuppressant therapy\n* Patients with no or limited access to either a telephone or mobile phone, as well as those without reliable internet access","ALL","18 Years","65 Years",{"count":20,"type":21},154,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to find out whether a pharmacist-led tele-educational program (PharmaTE trial) can help people with type 2 diabetes manage their condition better.\n\nThe main questions this study aims to answer are:\n\n1. Does the PharmaTE trial improve blood sugar control (HbA1c levels)?\n2. Does it help patients better understand their condition?\n3. Does it increase how well patients follow their medication schedule?\n4. Does it improve the quality of life for patients with type 2 diabetes?\n5. Is this type of tele-education program feasible and acceptable for patients?\n\nParticipants will:\n\nBe randomly placed into one of two groups:\n\nIntervention group: Receive five virtual education sessions with a clinical pharmacist over the phone or via Zoom (each lasting 20-30 minutes), in addition to their usual diabetes care.\n\nControl group: Continue receiving standard diabetes care from their healthcare team without the additional pharmacist-led sessions.\n\nComplete assessments at the beginning and end of the study. These include:\n\nA blood test for HbA1c\n\n, Questionnaires on diabetes knowledge, medication adherence, and quality of life\n\nSome participants in the intervention group will be invited for interviews after the sessions to share their experiences and opinions about the program.\n\nWho can join? Adults aged 18-65 with uncontrolled type 2 diabetes (HbA1c \\> 7%), receiving care at Ibrahim Bin Hamad Obaidullah Hospital in Ras Al-Khaimah, who speak Arabic and can provide consent.",[27,28,29,30,31],"Type 2 Diabetes (T2DM)","Glycemic Control","Diabetes Knowledge","Medication Adherence","Quality of Life",[14],"NOT_YET_RECRUITING","2026-04-28",{"date":36,"type":37},"2026-04-29","ACTUAL",{"date":39,"type":21},"2026-09-01",{"date":41,"type":21},"2027-12-31",{"name":43,"class":44},"Rabia Hussain","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":61,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100630708","effect-of-glycemic-control-on-intraoperative-nirs-and-postoperative-recovery-in-diabetic-patients-100630708","NCT07491185","Effect of Glycemic Control on Intraoperative NIRS and Postoperative Recovery in Diabetic Patients","Effects of Intraoperative Near-Infrared Spectroscopy and Postoperative Recovery on Glycemic Control Levels in Patients With Diabetes Mellitus: A Prospective Study","NIRS-DM","Inclusion Criteria:\n\n* Age ≥18 years\n* Patients scheduled for elective urologic surgery under general anesthesia\n* ASA physical status I-III\n* Patients with diabetes mellitus or non-diabetic control patients\n* Availability of preoperative HbA1c measurement\n* Written informed consent obtained\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* ASA physical status \\>III\n* Emergency surgery\n* History of cerebrovascular disease or neurological disorder\n* Previous brain or neurological surgery\n* Inability to communicate or refusal to participate\n* Intraoperative hemodynamic instability\n* Inadequate NIRS monitoring data",{"count":54,"type":21},80,"OBSERVATIONAL","This prospective observational study aims to evaluate the effect of glycemic control level on intraoperative cerebral oxygenation measured by near-infrared spectroscopy (NIRS) and postoperative recovery in patients with diabetes mellitus undergoing elective urologic surgery under general anesthesia.\n\nPatients will be grouped according to HbA1c levels to assess the relationship between long-term glycemic control and intraoperative regional cerebral oxygen saturation, hemodynamic parameters, and postoperative recovery scores.",[58,28,59,60],"Diabetes Mellitus","Cerebral Oxygenation","Anesthesia",[58,28,62,63],"Near-Infrared Spectroscopy","Postoperative Recovery","RECRUITING","2026-03-18",{"date":67,"type":37},"2026-03-24",{"date":69,"type":37},"2025-11-01",{"date":71,"type":21},"2027-03",{"name":73,"class":44},"Ege University",1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":82,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":86,"conditions":87,"keywords":90,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":74},"100604403","effect-of-chronic-exposure-to-nextida-gc-b-on-glycemic-control-in-adults-with-normoglycemia-or-prediabetes-100604403","NCT07149064","Effect of Chronic Exposure to Nextida GC-B on Glycemic Control in Adults With Normoglycemia or Prediabetes","A Randomized, Triple-blind, Placebo Controlled, Parallel Clinical Trial to Investigate the Efficacy and Safety of Chronic Exposure to Nextida GC-B on Glycemic Control in Adults With Normoglycemia or Prediabetes","Inclusion Criteria:\n\n1. Males and females 18 years and older\n2. BMI of 25 to 34.9 kg\u002Fm2, inclusive\n3. Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening\n\n   Or,\n\n   Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:\n   1. Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)\n   2. Double-barrier method\n   3. Intrauterine devices\n   4. Non-heterosexual lifestyle and agrees to use contraception if planning on changing to heterosexual partner(s)\n   5. Vasectomy of partner at least 6 months prior to screening\n   6. Abstinence and agrees to use contraception if planning on becoming sexually active during the study\n4. Individuals with normoglycemia (HbA1c ≤5.9%) or prediabetes (HbA1c 6.0 to ≤6.4%) at screening\n5. Stable body weight defined as a \\\u003C5% change in body weight in the three months prior to baseline as assessed by the Qualified Investigator (QI)\n6. Agrees to maintain current lifestyle habits (diet, physical activity, medications, supplements, sleep, and skin, nail and hair habits) as much as possible throughout the study\n7. Willingness to complete questionnaires, records and diaries associated with the study, comply with continuous glucose monitor (CGM) device instructions, and complete all clinic visits\n8. Provided voluntary, written, informed consent to participate in the study\n9. Healthy as determined by medical history and laboratory results as assessed by QI\n\nExclusion Criteria:\n\n1. Individuals who are pregnant, breast feeding, or planning to become pregnant during the study\n2. Allergy, sensitivity, intolerance, or dietary restriction preventing consumption of investigational product, placebo or standardized meal ingredients\n3. Metal implants or other physical characteristics\u002Flimitations that may affect DEXA scan results as assessed by the QI\n4. Poor venous access as assessed by the QI\n5. Current use of prescribed and\u002For over-the-counter (OTC) medications, supplements, and\u002For consumption of food\u002Fdrinks that may impact the efficacy and\u002For safety of the investigational product (Section 7.3)\n6. Unstable metabolic disease or chronic diseases as assessed by the QI\n7. Current or history of any significant diseases of the gastrointestinal tract as assessed by the QI\n8. Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI\n9. Type I or Type II diabetes\n10. Significant cardiovascular event in the past 6 months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case-by-case basis\n11. History of or current diagnosis with kidney and\u002For liver diseases as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones in participants who are symptom free for 6 months\n12. Self-reported confirmation of current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least 3 months will be considered by the QI\n13. Major surgery in the past 3 months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the QI\n14. Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable\n15. Individuals with an autoimmune disease or are immune compromised as assessed by the QI\n16. Self-reported confirmation of a HIV-, Hepatitis B- and\u002For C-positive diagnosis as assessed by the QI\n17. Self-reported confirmation of blood\u002Fbleeding disorders as assessed by the QI\n18. Use of medical cannabinoid products\n19. Chronic use of cannabinoid products (\\>2 times\u002Fweek). Occasional users will be required to washout and abstain for the duration of the study period\n20. Regular use of tobacco or nicotine products in the past six months, as assessed by the QI. Occasional users will be required to washout and abstain for the duration of the study period\n21. Alcohol intake average of \\>2 standard drinks per day as assessed by the QI\n22. Alcohol or drug abuse within the last 12 months\n23. Clinically significant abnormal laboratory results at screening as assessed by the QI\n24. Blood donation 30 days prior to baseline, during the study, or a planned donation within 30 days of the last study visit\n25. Participation in other clinical research studies 30 days prior to baseline, as assessed by the QI\n26. Individuals who are unable to give informed consent\n27. Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant",true,{"count":84,"type":21},60,[24],"The goal of this clinical trial is to investigate the safety and efficacy of Nextida GC-B on glycemic control in adults with normoglycemia and prediabetes. The main question it aims to answer is:\n\nWhat is the difference in change in postprandial glycemic control from baseline at Day 90 between Nextida GC-B and placebo as assessed by glucose incremental AUC (iAUC 0-180 min).",[88,89,28],"Normoglycemia","Prediabetes",[91,92,93,89,94],"Nextida GC-B","glycemic control","normoglycemia","postprandial glycemic control","2026-03-12",{"date":97,"type":37},"2026-03-16",{"date":99,"type":37},"2026-02-18",{"date":101,"type":21},"2026-08",{"name":103,"class":104},"Rousselot BVBA","INDUSTRY",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":16,"minAge":113,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":22,"phases":116,"briefSummary":117,"conditions":118,"keywords":127,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":140},"100578896","how-a-mediterranean-diet-with-potatoes-impacts-heart-and-metabolic-health-in-adults-with-pre-diabetes-100578896","NCT06817252","How a Mediterranean Diet With Potatoes Impacts Heart and Metabolic Health in Adults With Pre-Diabetes","Effects of a Mediterranean Dietary Pattern With White Potato on Cardiometabolic Health in Adults With Pre-Diabetes","MEDPOT-PREDM","Inclusion Criteria:\n\n* Men and postmenopausal women within the Las Vegas\u002FHenderson NV area\n* Ages 45-80 years\n* BMI between 25-40 kg\u002Fm2\n* HbA1c between 5.7-6.4%\n* Individuals from different demographic backgrounds (i.e., American Indian or Alaska Native, Caucasians, Asian, Black or African-American, Native Hawaiian, Hispanic, Latino or Pacific Islander)\n* Individuals who are considered \"non-frequent\" white potato consumers (\\\u003C2 servings of baked potatoes\u002Fweek)\n* Individuals from all races, genders, sexual identities, and religions will be included\n* Individuals must follow certain guidelines, including avoiding new medications during the study or significant changes to lifestyle factors (e.g. beginning to smoke or exercise more or less than usual)\n\nExclusion Criteria:\n\n* Individuals with uncontrolled hypertension (≥160\u002F100mmHg), active cancer, asthma, thyroid, kidney, liver, or pancreatic diseases\n* Individuals who are currently using insulin, on dialysis, changing\u002Fadding hypoglycemic, anti-hypertensive, and hypocholesterolemic medication within ≤3 months (or throughout the study)\n* Individuals participating in weight loss programs or another clinical trial\n* Individuals who start smoking\n* Individuals who have unstable metabolic or chronic diseases\n* Individuals who may have allergies to potatoes\n* Woman who are currently pregnant, think they may be pregnant, or who is nursing cannot participate (women must be postmenopausal)","45 Years","80 Years",{"count":84,"type":21},[24],"The goal of this clinical trial is to is to determine the effects of baked potato with the skin (BP) + nutrition education focused on adherence for a Mediterranean Dietary Pattern (MEDNE) on glycemic control, cardiometabolic health, and dietary quality in individuals with pre-diabetes from different demographic backgrounds. The main questions it aims to answer are:\n\n* Does BP+MEDNE contribute to improvements in indices of glycemic control, vascular function, blood lipids, inflammation\u002Foxidative stress, and body composition?\n* Does BP+MEDNE contribute to improvements to overall dietary intake and quality?\n\nResearchers will compare BP+MEDNE to MEDNE alone to see if BP+MEDNE can improve glycemic control, cardiometabolic health, and dietary quality in individuals with pre-diabetes from different demographic backgrounds.\n\nParticipants will:\n\n* Be asked to come to the study site initially for a Screening Study Visit to confirm eligibility.\n* Be asked to come the study site for a Pre-Baseline and Pre-12-Week Study Visit (one week prior to Baseline and 12-Week Study Visits) for placement of placement of a continuous glucose monitor and wearable devices to be removed at Baseline and 12-Week Study Visits.\n* Be asked to come to the study site for Baseline, 6- and 12-Week Study Visits for assessments of glycemic control and cardiometabolic health.\n* Be asked to complete 3-Day Food Records throughout the 12 week study period for assessment of dietary quality (5 total)\n* Receive pre-recorded MEDNE ( which can be accessed via computer device\u002Fipad\u002Fsmartphone) after Baseline and 6-Week Study Visits.\n* If randomized to the BP+MEDNE group, participants will receive pre-prepared baked potatoes with the skin for the 12-week study period (every 3 weeks) at Baseline and 6-Week Study Visits and asked to come to the study site for picking up the pre-prepared baked potatoes at weeks 3 and 9 of the study period.",[89,119,120,28,121,122,123,124,125,126],"Lipid Profile","Hypertension","Arterial Stiffness, Blood Pressure","Inflammation Biomarkers","Dietary Quality","Body Composition Measurement","Waist Circumference","Anthropometrics: Height and Weight",[128,89,129,130,123],"White Potato","Mediterranean Diet","Cardiometabolic Health","2025-11-17",{"date":133,"type":37},"2025-11-20",{"date":135,"type":37},"2025-04-24",{"date":137,"type":21},"2026-12-31",{"name":139,"class":44},"University of Nevada, Las Vegas",2,{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":149,"targetDuration":4,"studyType":22,"phases":151,"briefSummary":153,"conditions":154,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":74},"100488792","phase-4-effect-of-erugliflozin-on-liver-fat-liver-fibrosis-and-glycemic-control-in-type-ii-dm-patients-with-nashnafld-100488792","NCT05644717","Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH\u002FNAFLD","Effects of Ertugliflozin on Liver Fat, Liver Fibrosis & Glycemic Control in Subjects With Type 2 Diabetes Mellitus (T2DM) & Non-Alcoholic Fatty Liver Disease \u002FNon-Alcoholic Steatohepatitis","Ertu-NASH","Inclusion Criteria:\n\n* Patient able to provide written informed consent\n* Adult males \\& females between 18 to 65 years\n* SGLT2i and insulin naïve patients\n* BMI \\>23 Kg\u002Fm2\n* HbA1C % ≥ 6.5 to 10\n* Documented hepatic steatosis or fatty liver disease on Ultrasound\n* Patient with Type II Diabetes Mellitus\n\nExclusion Criteria:\n\n* History of use of SGLT 2 inhibitors or Glucagon-like peptide (GLP) 1 agonist or insulin; 3 months prior to enrollment in the study.\n* Pioglitazone use in the past 6 months\n* History of vitamin E use (400mg twice daily) 3 months prior to enrollment in the study.\n* History of anti-obesity medication or weight loss procedure (bariatric surgery) use within 3 months prior to enrollment in the study.\n* History of uncontrolled Endocrine disorder (for example uncontrolled hypothyroidism, or that requires frequent dose adjustment, or Cushing's syndrome)\n* History of liver disease including viral hepatitis, auto-immune hepatitis, liver cirrhosis, hepatocellular carcinoma and\u002For HIV\n* History of recurrent UTIs and mycotic infection.\n* Severely ill patients (who have high grade fever, sepsis or acute infection)\n* Pregnant woman, lactating woman or planning pregnancy during study duration\n* History of Drug-induced liver disease (e.g. amiodarone, valproate, tamoxifen, methotrexate, steroids (including homeopathic medicines).\n* History of active substance abuse (cannabinoid-derived substances like heroin, cocaine, amphetamines) based on history and\u002For laboratory tests\n* Alcohol intake 10 - 30 g\u002Fday (three drinks per day) within the previous year\n* Active substance abuse such as acetaminophen over-use, hashish, tobacco products, heroin, cocaine or amphetamines.\n* Severe hepatic impairment ( AST \\& ALT levels \\> 3 times upper limit normal",{"count":150,"type":21},164,[152],"PHASE4","Open-label, prospective, single-arm, multicenter study to determine effects of Ertugliflozin on liver fat, liver fibrosis \\& glycemic control in subjects with Type 2 Diabetes Mellitus (T2DM) with Non-Alcoholic Fatty Liver Disease (NAFLD)\u002FNon-Alcoholic Steatohepatitis (NASH)",[155,156,28,157,125,158],"Liver Fat","Liver Fibrosis","Body Weight Changes","Tolerance","2025-03-19",{"date":161,"type":37},"2025-03-21",{"date":163,"type":37},"2023-03-01",{"date":165,"type":21},"2025-12-01",{"name":167,"class":104},"Getz Pharma",{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":16,"minAge":175,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":22,"phases":178,"briefSummary":179,"conditions":180,"keywords":182,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":74},"100578384","comparing-efficacy-between-two-protocols-of-intravenous-insulin-infusion-for-diabetic-adults-in-icu-100578384","NCT06810596","Comparing Efficacy Between Two Protocols of Intravenous Insulin Infusion for Diabetic Adults in ICU","Comparing Glycemic Control Efficacy Between The National Health System and Suez Canal University Protocols of Intravenous Insulin Infusion for Diabetic Adults in ICU","Inclusion Criteria:\n\n* Patients who admitted to the hospital with a potentially life-threatening condition (Critically ill patients) with HbA1C \\>6.0.\n\nExclusion Criteria:\n\n* DKA patients.\n* Pregnant or breast-feeding patients.\n* Hyperosmolar Non-Ketotic Coma.","19 Years",{"count":177,"type":21},100,[24],"The goal of clinical trial is to improve the adequacy of blood sugar control in diabetic critically ill adult patients who admitted to the intensive care unit(ICU) in Suez Canal University (SCU) hospitals by comparing glycemic control efficacy between the NHS in the UK and suggested SCU Protocols of Intravenous Insulin Infusion.\n\nThe main questions it aims to answer are:\n\nIs SCU protocol of Intravenous Insulin Infusion more effective than NHS protocol in achieving blood glucose control targets in critically ill adult patients?\n\nResearchers will compare glycemic control efficacy between the NHS in UK and suggested SCU Protocols of Intravenous Insulin Infusion for critically ill Adults in ICU to determine the best protocol in achieving good blood glucose control in diabetic critically ill adult patients in SCU Hospitals.",[28,181,58],"Critical Care",[28,183,184],"Insulin Infusion Protocol","Critically ill","2025-01-31",{"date":187,"type":37},"2025-02-05",{"date":189,"type":37},"2024-12-15",{"date":191,"type":21},"2025-04-15",{"name":193,"class":44},"Suez Canal University",{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":200,"eligibilityCriteria":201,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":202,"targetDuration":4,"studyType":22,"phases":204,"briefSummary":205,"conditions":206,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":74},"100483107","latinos-understanding-the-need-for-adherence-in-diabetes-using-e-health-100483107","NCT05570734","Latinos Understanding the Need for Adherence in Diabetes Using E-Health","Latinos Understanding the Need for Adherence in Diabetes Using Care Coordination, Integrated Medical and Behavioral Care and E-Health","LUNA-E","Inclusion Criteria:\n\n1. Self identify as Hispanic\u002FLatino ethnicity of any race\n2. Registered patient of federally qualified health center\n3. 18 years of age or older\n4. Type 2 diabetes with hemoglobin A1C (HbA1c) \\>7.5% in past 90 days\n5. Approval from primary care provider\n6. Not currently enrolled\u002Fparticipating in any other diabetes intervention program(s)\n\nExclusion Criteria:\n\n1. Actively being treated for cancer or Parkinson's Disease\n2. Pregnant or nursing (temporary exclusion, may qualify 6-months postpartum)\n3. Have plans to move out of the area in the next 12 months\n4. Have other existing mental or physical health problems so severe as to prohibit informed consent and participation\n5. Have severe diabetes complications (e.g., renal disease, or on dialysis)",{"count":203,"type":21},400,[24],"Latinos Understanding the Need for Adherence in Diabetes using Care Coordination, Integrated Medical and Behavioral Care and E-Health (LUNA-E) is a randomized controlled trial (RCT) that will test the effectiveness a patient-centered, team-based, primary care intervention with E-Health enhancements in improving glycemic control (primary outcome, hemoglobin A1C level) and psychological distress (secondary outcome; depression, anxiety symptoms).",[207,28,208],"Type 2 Diabetes","Psychological Distress","2025-01-15",{"date":211,"type":37},"2025-01-17",{"date":213,"type":37},"2023-02-27",{"date":215,"type":21},"2026-02",{"name":217,"class":44},"San Diego State University",{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":82,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":225,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":227,"conditions":228,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":4},"100574633","effect-the-glycemic-control-on-cardiac-function-100574633","NCT06761820","Effect the Glycemic Control on Cardiac Function","Evaluation the Effect of Glycemic Control on Cardiac Function in Patients with Type 2 Diabetes Mellitus","Inclusion Criteria:\n\n* type 2 diabetic patients with heart diseases\n\nExclusion Criteria:\n\n* patients with type 1 diabetes mellitus\n* gestational DM\n* CKD patients requiring haemodialysis\n* Immune system disorder",{"count":226,"type":21},200,"Evaluation of the effect of the Glycemic control on cardiac function in patients with type 2 diabetes mellitus",[229,28],"Cardiac Function","2025-01-06",{"date":232,"type":37},"2025-01-07",{"date":234,"type":21},"2025-04",{"date":236,"type":21},"2026-12",{"name":238,"class":44},"Assiut University"]